An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder characterized by ineffective blood cell production and a predisposition to the development of leukemia. Patients with an interstitial deletion of Chromosome 5q...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS medicine 2008-02, Vol.5 (2), p.e35
Hauptverfasser: Ebert, Benjamin L, Galili, Naomi, Tamayo, Pablo, Bosco, Jocelyn, Mak, Raymond, Pretz, Jennifer, Tanguturi, Shyam, Ladd-Acosta, Christine, Stone, Richard, Golub, Todd R, Raza, Azra
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!